VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2019 | CUPISCO & GEFCAPI04: molecularly-guided therapy in cancer of unknown primary

Kai-Keen Shiu, FRCP, PhD, University College London Hospitals NHS Foundation Trust, London, UK, gives us an update on the CUPISCO trial (NCT03498521). This Phase II study compares the efficacy and safety of targeted therapy or immunotherapy guided by genomic profiling versus standard platinum-containing chemotherapy in participants with cancer of unknown primary site (CUP). Dr Shiu also discusses the implications of the GEFCAPI04 trial (NCT01540058). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter